Russell Investments Group’s Galectin Therapeutics GALT Stock Holding History

Russell Investments Group’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.4K	Buy	3,974 +3,832	+2,699%	+$9.93K	﹤0.01%	3822
2026 Q1	$396	Sell	142 -17,932	-99%	-$54.5K	﹤0.01%	4112
2025 Q4	$75.2K	Buy	18,074 +17,895	+9,997%	+$94.2K	﹤0.01%	3156
2025 Q3	$758	Hold	179	–	–	﹤0.01%	4062
2025 Q2	$378	Sell	179 -340	-66%	-$509	﹤0.01%	3767
2025 Q1	$633	Buy	+519	New	+$728	﹤0.01%	3650
2024 Q4	–	Sell	-740	Closed	-$2.04K	–	3734
2024 Q3	$2.04K	Buy	+740	New	+$1.82K	﹤0.01%	3373
2021 Q1	–	Sell	-106,075	Closed	-$237K	–	3134
2020 Q4	$237K	Hold	106,075	–	–	﹤0.01%	2708
2020 Q3	$283K	Buy	+106,075	New	+$297K	﹤0.01%	2633

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Russell Investments Group's GALT Position: Q2 2026 in Review

Russell Investments Group increased its Galectin Therapeutics (GALT) stake by 2,699% in Q2 2026, buying an estimated $9.93K and bringing the position to 3,974 shares worth $18.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3822.

Russell Investments Group first reported a position in GALT in Q3 2020 and has held it in 9 quarters since. The position peaked at $283K in Q3 2020. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

Russell Investments Group held 3,974 shares of Galectin Therapeutics worth $18.4K as of Q2 2026.
Russell Investments Group bought 3,832 Galectin Therapeutics shares in Q2 2026, an estimated $9.93K.
Galectin Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3822 holding.
Russell Investments Group first reported a position in Galectin Therapeutics in Q3 2020 and has held it in 9 quarters since.
Russell Investments Group's Galectin Therapeutics position peaked at $283K in Q3 2020.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.